Therapeutic effects of Argyrin F in pancreatic adenocarcinoma
Related Experiment Video
Updated: Oct 12, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Xi Chen1, Khac Cuong Bui1, Samarpita Barat1
1Department of Internal Medicine I, Medical University Hospital, Tübingen, Germany.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited treatment options. The proteasome inhibitor Argyrin A, a cyclic peptide derived from the myxobacterium Archangium gephyra, shows antitumoral activities. We hypothesize that his analogue Argyrin F (AF) may also prevent PDAC progression. We have used PDAC cells and engineered mice (Pdx1-Cre; LSL-KrasG12D; p53 lox/+) to assess AF anticancer activity. We analyzed the effect of AF on proliferation and epithelial plasticity using MTT-, wound healing-, invasion-, colony formation-, apoptosis-, cell cycle- and senescence assays. In vivo treatment with AF, Gemcitabine (G) and combinational treatment (AF + G) was performed for survival analysis. AF inhibited cell proliferation, migration, invasion and colony formation in vitro. AF impaired epithelial-mesenchymal transition (EMT), caused considerable apoptosis and senescence in a dose- and time-dependent manner and affected cell cycle G1/S phase transition. G treatment achieved longest mice survival, followed by AF + G and AF compared to vehicle group. However, AF + G treatment induced the largest reduction in tumor spread and ascites. In conclusion, we have demonstrated that AF prevents PDAC progression and that combined therapy was superior to AF monotherapy. Therefore, AF treatment might be useful as an additional therapy for PDAC.
Insights
Argyrin F (AF) shows promise in preventing pancreatic ductal adenocarcinoma (PDAC) progression by inhibiting cell growth and spread. Combined AF and Gemcitabine therapy reduced tumor spread and ascites more effectively than monotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited therapeutic options.
- Argyrin A, a proteasome inhibitor, exhibits antitumoral properties.
- The potential of its analogue, Argyrin F (AF), in PDAC treatment warrants investigation.
Purpose of the Study:
- To evaluate the efficacy of Argyrin F (AF) in preventing pancreatic ductal adenocarcinoma (PDAC) progression.
- To assess the impact of AF on cancer cell proliferation, migration, invasion, and epithelial plasticity.
- To determine the therapeutic potential of AF, alone and in combination with Gemcitabine, in a preclinical PDAC model.
Main Methods:
- In vitro assays (MTT, wound healing, invasion, colony formation, apoptosis, cell cycle, senescence) were used to analyze AF's effects on PDAC cells.
- Engineered mice (Pdx1-Cre; LSL-KrasG12D; p53lox/+) were used for in vivo studies.
- Survival analysis and tumor burden assessment were performed for AF, Gemcitabine (G), and combination treatments (AF + G).
Main Results:
- Argyrin F (AF) inhibited PDAC cell proliferation, migration, invasion, and colony formation in vitro.
- AF treatment led to apoptosis and senescence, impaired epithelial-mesenchymal transition (EMT), and affected cell cycle progression.
- In vivo, combination therapy (AF + G) significantly reduced tumor spread and ascites, although Gemcitabine monotherapy provided the longest survival.
Conclusions:
- Argyrin F (AF) demonstrates significant potential in preventing pancreatic ductal adenocarcinoma (PDAC) progression.
- Combined therapy with AF and Gemcitabine offers superior reduction in tumor spread and ascites compared to monotherapy.
- AF represents a promising candidate for adjunct therapy in PDAC treatment strategies.
